About Glycogen synthase kinase-3 beta
Glycogen synthase kinase-3 beta (GSK3B) is a protein
from Homo sapiens identified by UniProt accession
P49841, 420 residues long.
MolForge cross-references it against 0 known binders and
1,039 disease associations.
Target properties
| Protein name | Glycogen synthase kinase-3 beta |
| UniProt accession | P49841 |
| Gene | GSK3B |
| Organism | Homo sapiens |
| Length | 420 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (14)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (1039)
Diseases linked to this target (Open Targets).
- bipolar disorder · score 0.63
- depressive disorder · score 0.58
- bipolar I disorder · score 0.58
- cancer · score 0.56
- major depressive disorder · score 0.55
- Alzheimer disease · score 0.54
- Parkinson disease · score 0.53
- multiple sclerosis · score 0.52
- neurodegenerative disease · score 0.52
- lysosomal storage disease · score 0.51
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P49841-F1 | alphafold | PREDICTED | 88.23 | — |
Amino-acid sequence (420 residues)
MSGRPRTTSF AESCKPVQQP SAFGSMKVSR DKDGSKVTTV VATPGQGPDR PQEVSYTDTK VIGNGSFGVV YQAKLCDSGE LVAIKKVLQD KRFKNRELQI MRKLDHCNIV RLRYFFYSSG EKKDEVYLNL VLDYVPETVY RVARHYSRAK QTLPVIYVKL YMYQLFRSLA YIHSFGICHR DIKPQNLLLD PDTAVLKLCD FGSAKQLVRG EPNVSYICSR YYRAPELIFG ATDYTSSIDV WSAGCVLAEL LLGQPIFPGD SGVDQLVEII KVLGTPTREQ IREMNPNYTE FKFPQIKAHP WTKVFRPRTP PEAIALCSRL LEYTPTARLT PLEACAHSFF DELRDPNVKL PNGRDTPALF NFTTQELSSN PPLATILIPP HARIQAAAST PTNATAASDA NTGDRGQTNN AASASASNST
Explore Glycogen synthase kinase-3 beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets